Thyroid vascularization is an important ultrasonographic parameter in untreated Graves' disease patients.
Doppler
Echopattern
FT3, triiodothyronine
FT4, thyroxine
Graves disease
Hyperthyroidism
Hypoechoic
TRAb, thyrotropin-receptor antibodies
TSH, thyrotropin
Ultrasonographic pattern
Ultrasonography
Vascularization
Journal
Journal of clinical & translational endocrinology
ISSN: 2214-6237
Titre abrégé: J Clin Transl Endocrinol
Pays: Netherlands
ID NLM: 101629335
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
22
12
2018
revised:
17
01
2019
accepted:
17
01
2019
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
23
2
2019
Statut:
epublish
Résumé
Graves' disease is characterized by two sonographic features, hypoechogenicity and increased blood flow. The aim of this study was to review retrospectively ultrasound features and biochemical data of a cohort of untreated Graves' disease patients. We reviewed charts of 42 such patients, who were referred to our Endocrinology Unit from January 2013 to May 2018. One operator performed all the thyroid sonographic scans. Serum TSH, FT3, FT4 and TSH-receptor antibodies (TRAb) levels at the time of ultrasound examination were evaluated. Over a mean follow-up of 30.9 months, about one in three patients (38%) experienced at least one recurrence of hyperthyroidism (1.4 ± 0.6 recurrence per patient), either on or off antithyroid drugs. We found that thyroid vascularization correlated directly with thyroid volume and that larger thyroids tended to be more vascularized. We also found that greater vascularization was associated with marked hypoechogenicity, and greater FT4 and TRAb levels. Patients who experienced recurrence(s) had 1.7-fold higher levels of TRAb at onset. In conclusion, thyroid hypervascularization at onset of Graves' disease is an important sonographic feature.
Identifiants
pubmed: 30792955
doi: 10.1016/j.jcte.2019.01.001
pii: S2214-6237(18)30159-5
pmc: PMC6370557
doi:
Types de publication
Journal Article
Langues
eng
Pagination
65-69Références
Eur J Endocrinol. 1999 May;140(5):452-6
pubmed: 10229913
Eur J Radiol. 2000 Oct;36(1):5-10
pubmed: 10996751
Arch Surg. 2003 Feb;138(2):146-51; discussion 151
pubmed: 12578408
Acta Endocrinol (Copenh). 1992 Feb;126(2):128-31
pubmed: 1543017
Clin Endocrinol (Oxf). 2005 Dec;63(6):657-62
pubmed: 16343100
Thyroid. 2007 Mar;17(3):223-8
pubmed: 17381355
Eur J Radiol. 2008 Jan;65(1):99-103
pubmed: 17459638
Endocr J. 2008 May;55(2):345-50
pubmed: 18379127
Endocr Pract. 2009 Jan-Feb;15(1):6-9
pubmed: 19211390
J Clin Endocrinol Metab. 1991 Jan;72(1):209-13
pubmed: 1986019
West Indian Med J. 2009 Dec;58(6):566-70
pubmed: 20583684
World J Radiol. 2013 Apr 28;5(4):178-83
pubmed: 23671754
Eur Thyroid J. 2013 Jun;2(2):120-6
pubmed: 24783050
Endocrine. 2015 Feb;48(1):254-63
pubmed: 24853882
Autoimmun Rev. 2015 Feb;14(2):174-80
pubmed: 25461470
Eur Thyroid J. 2015 Sep;4(3):149-63
pubmed: 26558232
Endocrine. 2017 Jan;55(1):93-100
pubmed: 26951052
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
Ann Med Surg (Lond). 2016 Aug 08;10:69-72
pubmed: 27570620
Ann Endocrinol (Paris). 2018 Dec;79(6):647-655
pubmed: 30180972
Ann Endocrinol (Paris). 2018 Dec;79(6):608-617
pubmed: 30220410
J Endocrinol Invest. 2018 Dec;41(12):1435-1443
pubmed: 30327945
World J Surg. 1988 Aug;12(4):470-5
pubmed: 3047999
AJR Am J Roentgenol. 1988 Apr;150(4):781-4
pubmed: 3279732
AJR Am J Roentgenol. 1996 Jan;166(1):203-7
pubmed: 8571877
J Endocrinol Invest. 1995 Dec;18(11):857-61
pubmed: 8778158
Clin Endocrinol (Oxf). 1996 Aug;45(2):201-6
pubmed: 8881453
J Endocrinol Invest. 1996 Oct;19(9):603-6
pubmed: 8957744
Thyroid. 1997 Aug;7(4):541-5
pubmed: 9292940
Thyroid. 1998 Jul;8(7):577-82
pubmed: 9709910